Clinical utility of trial 1 of the Test of Memory Malingering (TOMM)

Sidney O'Bryant, Brandon E. Gavett, Robert J. McCaffrey, Judith Rosemary O'Jile, Justin K. Huerkamp, Todd A. Smitherman, Joy D. Humphreys

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The clinical utility of Trial 1 of the Test of Memory Malingering (TOMM) has recently become a topic of investigation. The current study cross-validated previous research suggesting that those participants who score 45 or greater on Trial 1 of the TOMM will continue to do so on Trial 2 and the Retention Trial and extended these findings to broader clinical and nonclinical populations. Two archival samples were included for analyses: one sample of healthy community-dwelling elders and another sample drawn from an outpatient neuropsychology clinic. As demonstrated previously, 100% of those patients that scored 45 or greater on TOMM Trial 1 scored above cut-scores on Trial 2 and the Retention Trial, supporting the utility of a possible discontinuation rule on Trial 1. When combined with previous research, the current results provide further support for the clinical utility of Trial 1 in predicting overall performance on the TOMM; however, use of any nonstandard administration of the TOMM may not satisfy Daubert criteria in forensic settings and may not be appropriate.

Original languageEnglish
Pages (from-to)113-116
Number of pages4
JournalApplied Neuropsychology
Volume15
Issue number2
DOIs
StatePublished - 1 Apr 2008

Fingerprint

Malingering
Clinical Trials
Independent Living
Neuropsychology
Ambulatory Care Facilities
Research
Population

Keywords

  • Effort
  • Malingering
  • Test of Memory Malingering (TOMM)
  • Validity

Cite this

O'Bryant, S., Gavett, B. E., McCaffrey, R. J., O'Jile, J. R., Huerkamp, J. K., Smitherman, T. A., & Humphreys, J. D. (2008). Clinical utility of trial 1 of the Test of Memory Malingering (TOMM). Applied Neuropsychology, 15(2), 113-116. https://doi.org/10.1080/09084280802083921
O'Bryant, Sidney ; Gavett, Brandon E. ; McCaffrey, Robert J. ; O'Jile, Judith Rosemary ; Huerkamp, Justin K. ; Smitherman, Todd A. ; Humphreys, Joy D. / Clinical utility of trial 1 of the Test of Memory Malingering (TOMM). In: Applied Neuropsychology. 2008 ; Vol. 15, No. 2. pp. 113-116.
@article{62b87716df0b45008ca962ed8899a638,
title = "Clinical utility of trial 1 of the Test of Memory Malingering (TOMM)",
abstract = "The clinical utility of Trial 1 of the Test of Memory Malingering (TOMM) has recently become a topic of investigation. The current study cross-validated previous research suggesting that those participants who score 45 or greater on Trial 1 of the TOMM will continue to do so on Trial 2 and the Retention Trial and extended these findings to broader clinical and nonclinical populations. Two archival samples were included for analyses: one sample of healthy community-dwelling elders and another sample drawn from an outpatient neuropsychology clinic. As demonstrated previously, 100{\%} of those patients that scored 45 or greater on TOMM Trial 1 scored above cut-scores on Trial 2 and the Retention Trial, supporting the utility of a possible discontinuation rule on Trial 1. When combined with previous research, the current results provide further support for the clinical utility of Trial 1 in predicting overall performance on the TOMM; however, use of any nonstandard administration of the TOMM may not satisfy Daubert criteria in forensic settings and may not be appropriate.",
keywords = "Effort, Malingering, Test of Memory Malingering (TOMM), Validity",
author = "Sidney O'Bryant and Gavett, {Brandon E.} and McCaffrey, {Robert J.} and O'Jile, {Judith Rosemary} and Huerkamp, {Justin K.} and Smitherman, {Todd A.} and Humphreys, {Joy D.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1080/09084280802083921",
language = "English",
volume = "15",
pages = "113--116",
journal = "Applied Neuropsychology",
issn = "0908-4282",
publisher = "Taylor and Francis Inc.",
number = "2",

}

O'Bryant, S, Gavett, BE, McCaffrey, RJ, O'Jile, JR, Huerkamp, JK, Smitherman, TA & Humphreys, JD 2008, 'Clinical utility of trial 1 of the Test of Memory Malingering (TOMM)', Applied Neuropsychology, vol. 15, no. 2, pp. 113-116. https://doi.org/10.1080/09084280802083921

Clinical utility of trial 1 of the Test of Memory Malingering (TOMM). / O'Bryant, Sidney; Gavett, Brandon E.; McCaffrey, Robert J.; O'Jile, Judith Rosemary; Huerkamp, Justin K.; Smitherman, Todd A.; Humphreys, Joy D.

In: Applied Neuropsychology, Vol. 15, No. 2, 01.04.2008, p. 113-116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical utility of trial 1 of the Test of Memory Malingering (TOMM)

AU - O'Bryant, Sidney

AU - Gavett, Brandon E.

AU - McCaffrey, Robert J.

AU - O'Jile, Judith Rosemary

AU - Huerkamp, Justin K.

AU - Smitherman, Todd A.

AU - Humphreys, Joy D.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - The clinical utility of Trial 1 of the Test of Memory Malingering (TOMM) has recently become a topic of investigation. The current study cross-validated previous research suggesting that those participants who score 45 or greater on Trial 1 of the TOMM will continue to do so on Trial 2 and the Retention Trial and extended these findings to broader clinical and nonclinical populations. Two archival samples were included for analyses: one sample of healthy community-dwelling elders and another sample drawn from an outpatient neuropsychology clinic. As demonstrated previously, 100% of those patients that scored 45 or greater on TOMM Trial 1 scored above cut-scores on Trial 2 and the Retention Trial, supporting the utility of a possible discontinuation rule on Trial 1. When combined with previous research, the current results provide further support for the clinical utility of Trial 1 in predicting overall performance on the TOMM; however, use of any nonstandard administration of the TOMM may not satisfy Daubert criteria in forensic settings and may not be appropriate.

AB - The clinical utility of Trial 1 of the Test of Memory Malingering (TOMM) has recently become a topic of investigation. The current study cross-validated previous research suggesting that those participants who score 45 or greater on Trial 1 of the TOMM will continue to do so on Trial 2 and the Retention Trial and extended these findings to broader clinical and nonclinical populations. Two archival samples were included for analyses: one sample of healthy community-dwelling elders and another sample drawn from an outpatient neuropsychology clinic. As demonstrated previously, 100% of those patients that scored 45 or greater on TOMM Trial 1 scored above cut-scores on Trial 2 and the Retention Trial, supporting the utility of a possible discontinuation rule on Trial 1. When combined with previous research, the current results provide further support for the clinical utility of Trial 1 in predicting overall performance on the TOMM; however, use of any nonstandard administration of the TOMM may not satisfy Daubert criteria in forensic settings and may not be appropriate.

KW - Effort

KW - Malingering

KW - Test of Memory Malingering (TOMM)

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=45849116561&partnerID=8YFLogxK

U2 - 10.1080/09084280802083921

DO - 10.1080/09084280802083921

M3 - Article

C2 - 18568603

AN - SCOPUS:45849116561

VL - 15

SP - 113

EP - 116

JO - Applied Neuropsychology

JF - Applied Neuropsychology

SN - 0908-4282

IS - 2

ER -

O'Bryant S, Gavett BE, McCaffrey RJ, O'Jile JR, Huerkamp JK, Smitherman TA et al. Clinical utility of trial 1 of the Test of Memory Malingering (TOMM). Applied Neuropsychology. 2008 Apr 1;15(2):113-116. https://doi.org/10.1080/09084280802083921